Recent News

• 06.10.2025 - Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
• 05.20.2025 - Enlivex Selected to Present at Israeli BioMed 2025 Conference
• 04.23.2025 - Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
• 04.21.2025 - Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
• 04.03.2025 - Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Recent Filings

• 05.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.30.2025 - EX-99.1 EX-99.1
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 05.12.2025 - EFFECT Notice of Effectiveness
• 05.02.2025 - F-3 Registration statement by foreign private issuers
• 04.30.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 04.23.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.23.2025 - EX-99.1 EX-99.1
• 04.21.2025 - EX-99.1 EX-99.1